Edwards Lifesciences
1,019 hedge funds and large institutions have $32.1B invested in Edwards Lifesciences in 2020 Q1 according to their latest regulatory filings, with 106 funds opening new positions, 352 increasing their positions, 408 reducing their positions, and 166 closing their positions.
40% more call options, than puts
Call options by funds: $169M | Put options by funds: $121M
2.25% less ownership
Funds ownership: 248.93% → 246.68% (-2.2%)
7% less funds holding
Funds holding: 1,092 → 1,019 (-73)
14% less repeat investments, than reductions
Existing positions increased: 352 | Existing positions reduced: 408
20% less capital invested
Capital invested by funds: $40.3B → $32.1B (-$8.15B)
28% less funds holding in top 10
Funds holding in top 10: 29 → 21 (-8)
36% less first-time investments, than exits
New positions opened: 106 | Existing positions closed: 166
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$420M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
+$291M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$178M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$153M |
| 5 |
CG
Carmignac Gestion
Paris,
France
|
+$108M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$805M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$394M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$359M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$184M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$170M |
EW Hedge Fund Activity: Q1 2020 in Review
1,019 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2020, worth a combined $32.1B — down 20% from $40.3B a quarter earlier.
Sellers outnumbered buyers: 166 funds closed out of EW and 106 opened new positions — a net loss of 60 holders — while 408 trimmed existing stakes and 352 added.
The largest buyer was Wellington Management Group, adding an estimated $420M. The largest seller was Jennison Associates, cutting an estimated $805M.
- 1,019 institutional investors held Edwards Lifesciences (EW) as of Q1 2020, down from 1,092 in Q4 2019.
- Funds reported $32.1B of Edwards Lifesciences stock for Q1 2020, down 20% quarter-over-quarter.
- 106 funds opened new Edwards Lifesciences positions in Q1 2020 and 166 closed out, a net change of -60 holders.
- The largest Edwards Lifesciences buyer in Q1 2020 was Wellington Management Group, an estimated $420M added.
- The largest Edwards Lifesciences seller in Q1 2020 was Jennison Associates, an estimated $805M sold.
Based on aggregated 13F filings for Q1 2020.